EGFR and non-small cell lung carcinoma: For example, somatic variations in exons 18–21 of EGFR occur in approximately 10–15% of non–small cell lung cancer (NSCLC) tumors and are sensitizing to first-generation tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib [10].